ACIU: AC Immune SA Company Profile & Statistics

About

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.

Info & Links

CEO

Andrea Pfeifer

Headquarters

EPFL INNOVATION PARK, BUILDING B
LAUSANNE, V8 1015, SWITZERLAND

Auditor

PricewaterhouseCoopers SA

Share holders

250

Employees

161

AC Immune SA Statistics

Valuation Measures

Market Capitalization²

286.93M

Enterprise Value

249.47M

Enterprise Value/EBITDA(ttm)

-4.45

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

1.94

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

50.00%

Operating Margin(ttm)

Profit Margin(ttm)

-822.84%

Return on Equity(ttm)

-28.26%

Return on Invested Capital(ttm)

-29.70%

Return on Assets(ttm)

-18.98%

Income Statement

Revenue(ttm)

30.21M

Revenue Per Share(ttm)

Gross Profit(ttm)

30.21M

EBITDA(ttm)³

-56.00M

Net Income Available to Common(ttm)

-44.85M

Diluted EPS(ttm)

-0.46

Share Statistics

Beta (5Y Monthly)

1.26

52-Week Change

-13.43%

S&P 500 52-Week Change

27.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

Dividend Yield

0.00%

Float⁴

94.39M

% Held by Insiders

4.60%

% Held by Institutions

51.36%

Balance Sheet

Total Cash(mrq)

182.45M

Total Cash Per Share(mrq)

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

1.86%

Quick Ratio(mrq)

1.86%

Book Value Per Share(mrq)

Cash Flow

Operating Cash Flow Per Share(ytd)

0.69

Free Cash Flow(ytd)

68.66M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

ACIU

AC Immune SA

AC Immune SA Profile